Rimonabant (brand name Acomplia) is a medication used to treat obesity and related conditions. It works by blocking the CB1 receptor in the brain, reducing appetite and cravings for food. It is usually prescribed to those with a BMI (body mass index) over 30, and has been found to help people lose an average of 5-10% of their body weight. It can also help reduce cholesterol levels, blood pressure, and other risk factors associated with obesity. However, it has been linked to side effects such as depression and anxiety, and is no longer available in the United States and some other countries.
Rimonabant was an anorectic anti-obesity drug, meaning it aimed to suppress appetite and aid weight loss. However, it was withdrawn from the market due to safety concerns [1, 2]. Here's a breakdown of its key points:
History:
- Developed as the first-in-class selective blocker of cannabinoid receptor CB1 [1].
- Approved for use in Europe in 2006 under the trade names Acomplia and Zimulti [1].
- Withdrawn worldwide in 2008 due to an increased risk of serious psychiatric side effects [1, 2].
- Never received approval for use in the United States.
How it Worked:
- Targeted the endocannabinoid system, which plays a role in regulating appetite and energy balance [2].
- By blocking CB1 receptors, rimonabant aimed to decrease appetite and promote feelings of fullness [2].
Reasons for Withdrawal:
- Studies revealed an increased risk of depression, anxiety, and suicidal ideation in users, particularly those with a history of mental health issues [1, 2].
Current Status:
- No longer a commercially available medication due to safety concerns.
- Research on alternative weight-loss medications with more favorable safety profiles continues.
Important Note:
- This information is for general knowledge only and does not constitute medical advice.
- If you are struggling with weight management, consult a doctor or licensed dietitian about safe and effective strategies.